NASDAQ:ENTAEnanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ENTA shares have decreased by 7.9% and is now trading at $48.76.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Enanta Pharmaceuticals.

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 19th 2020.
View our earnings forecast for Enanta Pharmaceuticals.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.73) by $0.02. The biotechnology company had revenue of $18.70 million for the quarter, compared to analysts' expectations of $25.47 million. Enanta Pharmaceuticals had a return on equity of 0.49% and a net margin of 1.57%. The business's quarterly revenue was down 57.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 EPS.
View Enanta Pharmaceuticals' earnings history.

6 brokerages have issued 12-month target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $49.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $70.17 in the next twelve months. This suggests a possible upside of 43.9% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals.

Headlines about ENTA stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Enanta Pharmaceuticals.

Some companies that are related to Enanta Pharmaceuticals include Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), Biohaven Pharmaceutical (BHVN), ChemoCentryx (CCXI), Reata Pharmaceuticals (RETA), BridgeBio Pharma (BBIO), GW Pharmaceuticals PLC- (GWPH), PTC Therapeutics (PTCT), Opko Health (OPK), Insmed (INSM), Axsome Therapeutics (AXSM), Alkermes (ALKS) and Agios Pharmaceuticals (AGIO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU) and Alibaba Group (BABA).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.42%), Goldman Sachs Group Inc. (1.82%), Bank of New York Mellon Corp (0.96%), Man Group plc (0.85%), Russell Investments Group Ltd. (0.68%) and Marshall Wace LLP (0.66%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or.
View institutional ownership trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Man Group plc, Skandinaviska Enskilda Banken AB publ , Bank of America Corp DE, Aigen Investment Management LP, WINTON GROUP Ltd, Alps Advisors Inc., and Marshall Wace North America L.P..
View insider buying and selling activity for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Assenagon Asset Management S.A., PDT Partners LLC, AJO LP, Tudor Investment Corp Et Al, Swiss National Bank, Rafferty Asset Management LLC, and SG Americas Securities LLC.
View insider buying and selling activity for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $48.76.

Enanta Pharmaceuticals has a market capitalization of $978.71 million and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

The official website for Enanta Pharmaceuticals is www.enanta.com.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]